Perspective Therapeutics Announces Patent License Agreement With Mayo Clinic For The Rights To The PSMA Alpha-PET DoubLET Platform Technology For The Treatment Of PSMA-Expressing Cancers, With An Initial Focus On Prostate
Portfolio Pulse from Benzinga Newsdesk
Perspective Therapeutics has entered into a patent license agreement with Mayo Clinic for the PSMA Alpha-PET DoubLET platform technology, which is used for imaging and targeted therapy in PSMA-expressing cancers, primarily prostate cancer. The technology involves a double chelator design using isotopes 64/67Cu and 203/212Pb for radiopharmaceutical therapy (RPT).
January 05, 2024 | 1:18 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Perspective Therapeutics, which may be associated with the ticker CATX, has licensed a novel prostate cancer treatment technology from Mayo Clinic, potentially enhancing its product pipeline.
The licensing agreement with Mayo Clinic for the PSMA Alpha-PET DoubLET technology is likely to be viewed positively by investors as it strengthens Perspective Therapeutics' position in prostate cancer treatment. This could lead to increased investor confidence and a potential short-term uptick in the stock price of CATX, assuming CATX is the correct ticker for Perspective Therapeutics.
CONFIDENCE 70
IMPORTANCE 75
RELEVANCE 80